European Network of Transmission System Operators for Electricity

Verastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Wednesday, November 8, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Standard of care, NSCLC, Food, Pancreas, Anastrozole, Regulatory affairs, Ovarian cancer, GAAP, Pancreatic Cancer Action Network, Paclitaxel, Accelerated approval (FDA), ORR, European Network of Transmission System Operators for Electricity, Safety, Cancer, Therapy, Investment, Patient, General Administration of Sport of China, Verastem Oncology, Topotecan, Conference, Bank statement, Clinical trial, FRAME, Travel, Letrozole, RAMP, FDA, SOC, AACR, RAS, Research and development, The Annual Global Orgasm for Peace, GOG, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, KRAS, Senior, Pharmacokinetics, European Society of Gynaecological Oncology, Lung cancer, Table, Diagnosis, Pharmaceutical industry, Bank, Finance

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the third quarter ending September 30, 2023 and highlighted recent progress.

Key Points: 
  • Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the third quarter ending September 30, 2023 and highlighted recent progress.
  • Verastem Oncology ended the third quarter of 2023 with cash, cash equivalents and investments of $165.7 million.
  • Research & development expenses for the 2023 Quarter were $13.9 million, compared to $11.3 million for the 2022 Quarter.
  • Selling, general & administrative expenses for the 2023 Quarter were $7.4 million, compared to $6.4 million for the 2022 Quarter.

Verastem Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Tuesday, August 8, 2023
Research, FDA, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Topotecan, Pancreatic cancer, KRAS, Verastem Oncology, Avutometinib, Table, BIW, Pancreatic Cancer Action Network, Bank statement, General Administration of Press and Publication, Pancreas, Cancer, Paclitaxel, Anastrozole, GAAP, SOC, NSCLC, FRAME, Lung cancer, PFS, RAMP, Acquisition, HIV disease progression rates, RAS, Patient, Standard of care, Investment, European Society of Gynaecological Oncology, GOG, European Network of Transmission System Operators for Electricity, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research and development, Society, Breakthrough, ORR, Letrozole, Food, Safety, Pharmaceutical industry, Transformer

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the second quarter ending June 30, 2023 and highlighted recent progress.

Key Points: 
  • Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the second quarter ending June 30, 2023 and highlighted recent progress.
  • Verastem Oncology ended the second quarter of 2023 with cash, cash equivalents and investments of $183.1 million.
  • Research & development expenses for the 2023 Quarter were $12.9 million, compared to $14.9 million for the 2022 Quarter.
  • Selling, general & administrative expenses for the 2023 Quarter were $7.4 million, compared to $6.5 million for the 2022 Quarter.

Nexans wins record-breaking contract for the EuroAsia Interconnector

Retrieved on: 
Wednesday, July 19, 2023
Aurora, Celtic, Electricity, Transmission system, European Network of Transmission System Operators for Electricity, History, PCI, Projects of Common Interest, TenneT, HVDC, CO2, KV, Renewable energy, Tunnel, EU, Nexans, European, EuroAsia Interconnector

Subsea HVDC Mass Impregnated cables will be manufactured in Nexans’ facilities in Halden (Norway) and Futtsu (Japan) and will be installed by the state-of-the-art cable laying vessels Nexans Aurora and Nexans Skagerrak.

Key Points: 
  • Subsea HVDC Mass Impregnated cables will be manufactured in Nexans’ facilities in Halden (Norway) and Futtsu (Japan) and will be installed by the state-of-the-art cable laying vessels Nexans Aurora and Nexans Skagerrak.
  • “This record-breaking project demonstrates our capacity to innovate and push the limits of electrical transmission and distribution to meet an ever growing global need.
  • Nexans’ global electrification strategy is playing a key role in the world’s journey to a net zero future and we are excited that we have been selected to bring the development of the EuroAsia Interconnector to life”, stated Christopher Guérin, CEO of Nexans.
  • The EuroAsia Interconnector Israel-Cyprus-Greece electricity interconnector is a leading European project of common interest PCI 3.10 that ends the energy isolation of Cyprus and Israel, creates security of supply, significantly reduces the CO2 emissions, and serves the “Green Deal” of the European Commission”, said Nasos Ktorides, CEO of EuroAsia Interconnector.

Artelys Improves Energy Supply and Cost For 300+ Million Europeans Using FICO Optimization

Retrieved on: 
Thursday, April 6, 2023
Data Management, Technology, Professional Services, Other Energy, Utilities, Other Technology, Data Analytics, Software, Artificial Intelligence, Other Professional Services, Energy, Heart, Partnership, Gabay, Failure, Electricity, TSO, Multimedia, Artelys Knitro, Nature, FICO Xpress, ESG, FICO, New European Transmission System, European Network of Transmission System Operators for Electricity, Cryptocurrency, Renewable energy, Electric power

View the full release here: https://www.businesswire.com/news/home/20230406005075/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230406005075/en/
    Artelys has optimized the energy supply for 300 million Europeans using FICO technology.
  • The TERRE platform ensures the balancing of power systems and security of supply at an efficient cost for more than 300 million Europeans.
  • “As a FICO partner, Artelys’ expertise in mathematical optimization applied to the energy sector has enabled FICO to consolidate its position as one of the leading optimization solvers for energy applications in Europe,” said Nicolas Omont, vice president of operations at Artelys.
  • “We at FICO applaud Artelys for their ground-breaking achievement, which will help make energy supply more reliable and affordable across Europe.”
    For its achievements, Artelys has won the ESG Champion award in the 2023 FICO® Decisions Awards.

Nuvectis Pharma, Inc. Reports Fiscal Year 2022 Financial Results and Business Highlights

Retrieved on: 
Tuesday, March 7, 2023
IND, Platinum, Investment, Publication, Criticism of the Food and Drug Administration, SRC, Medicine, Cancer, Lung cancer, Investigational New Drug, Research, Prostate cancer, Disease, American Association for Cancer Research, Castration, Treatment, Horizon, Gynecologic oncology, European Network of Transmission System Operators for Electricity, Patient, Food, YES1, Pharmaceutical industry, Cryptocurrency

Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented: "2022 was a very busy year for Nuvectis with significant progress made on both development programs.

Key Points: 
  • Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented: "2022 was a very busy year for Nuvectis with significant progress made on both development programs.
  • The increase of $14.3 million was primarily a result of the Company's initial public offering in February 2022 and the private placement in July 2022.
  • Research and development expenses for the 2022 fiscal year included $0.9 million in non-cash expenses.
  • General and administrative expenses for the 2022 fiscal year also included $0.8 million in non-cash expenses.

EQS-News: Photon Energy Group Acquires Majority Stake in Lerta, Plans Full Takeover before Year-end 2022

Retrieved on: 
Sunday, November 27, 2022
Photon, Independent power producer, Demand-side, Transmission system operator, Engineering, FSX, Acceleration, PV, Frankfurt Stock Exchange, VPP, Capacity building, Power, Solar energy, Electricity, Maintenance, Lord Howe Island, Thought, Professional, DSR, European Network of Transmission System Operators for Electricity, Plant, EUR, Photon energy, SSW, EPC, WSE, Transaction, CEE, Virtual power plant, Water resources, Nominal power (photovoltaic), IPP, Acquisition, Czech Republic, Financial services, Renewable energy, Cryptocurrency, Film, Retail, Polish

Photon Energy Group Acquires Majority Stake in Lerta, Plans Full Takeover before Year-end 2022

Key Points: 
  • Photon Energy Group Acquires Majority Stake in Lerta, Plans Full Takeover before Year-end 2022
    The issuer is solely responsible for the content of this announcement.
  • Photon Energy Group Acquires Majority Stake in Lerta, Plans Full Takeover before Year-end 2022
    Photon Energy Group increases its stake in Lerta from 24.27% to 56.75% and intends to acquire full control before year-end 2022.
  • Photon Energy Group intends to acquire the remaining equity from the two founding shareholders before year-end 2022.
  • Photon Energy N.V., the holding company for Photon Energy Group, is listed on the Warsaw, Prague and Frankfurt Stock Exchanges.

Aruna Anand Appointed New President and CEO of Continental Automotive North America

Retrieved on: 
Monday, November 21, 2022
Apps, Applications, Mobile, Wireless, Technology, Vehicle Technology, Automotive, General Automotive, Automotive Manufacturing, Software, Manufacturing, Hardware, Head, Woman, Automotive industry, Electronic control unit, Continental Automotive Systems, Automotive News, Electrical engineering, Anna University, Computer science and engineering, Continental AG, Continental, Multimedia, Gasoline, Electronics, Computer science, Transport, American Automotive Equipment, Spaun (Semantic Pointer Architecture Unified Network), European Network of Transmission System Operators for Electricity, Engineering, Growth, Leading Women, Airline, Management, Architecture, Oakland University, Drivetrain

Leading technology company Continental today announced that Aruna Anand has been named the new President and Chief Executive Officer of Continentals Automotive group sector in North America, effective December 1.

Key Points: 
  • Leading technology company Continental today announced that Aruna Anand has been named the new President and Chief Executive Officer of Continentals Automotive group sector in North America, effective December 1.
  • View the full release here: https://www.businesswire.com/news/home/20221121005768/en/
    A 25-year veteran of the Automotive industry, Aruna Anand was recently named the new North American President and CEO of Continentals Automotive Group Sector.
  • Aruna brings an outstanding combination of experience and talent to the President and CEO Automotive North America position, said Nikolai Setzer, CEO, Continental AG.
  • It is an honor to be selected as Automotive President and CEO for North America, Anand said.

Aravive Announces Approximately $41.5 Million Private Placement Financing

Retrieved on: 
Tuesday, October 25, 2022
Ovarian cancer, GAS6, Private Securities Litigation Reform Act, Terminology, Securities Act of 1933, Company, U.S. Securities and Exchange Commission, Cancer, Communication, GLOBE, Sale, Annual report, FDA, Tectonic evolution of the Aravalli Mountains, Patient, Quality of life, Platinum, SEC, DABT, Survival, Therapy, LLC, European Commission, PIPE, COVID-19, Paclitaxel, Risk, Exchange, Security (finance), Review, Forward-looking statement, Company Directors Disqualification Act 1986, Partnership, AXL, Doctor of Philosophy, Metastasis, European Network of Transmission System Operators for Electricity, Safety, Pharmaceutical industry, Nasdaq, PROC

The private placement is expected to close on October 27th, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The private placement is expected to close on October 27th, subject to the satisfaction of customary closing conditions.
  • The private placement is being conducted in accordance with applicable Nasdaq rules and was priced to satisfy the Minimum Price requirement (as defined in the Nasdaq rules).
  • MTS Securities, LLC, an affiliate of MTS Health Partners L.P., acted as the exclusive placement agent in the financing.
  • This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Aravive Receives Third Development Milestone from 3D Medicines

Retrieved on: 
Monday, October 10, 2022
Quality of life, Communication, European Network of Transmission System Operators for Electricity, Therapy, Risk, SEC, Review, GAS6, Hope, Woman, Platinum, Paclitaxel, Annual report, Patient, Metastasis, Partnership, Private Securities Litigation Reform Act, Company, Ovarian cancer, Marketing, Cancer, AXL, DABT, Safety, Survival, GLOBE, Clinical trial, Forward-looking statement, Tectonic evolution of the Aravalli Mountains, Terminology, COVID-19, PROC, European Commission, FDA, Pharmaceutical industry

HOUSTON, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Aravive Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that it received a $6 million development milestone payment from its licensee, 3D Medicines Inc.

Key Points: 
  • HOUSTON, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Aravive Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that it received a $6 million development milestone payment from its licensee, 3D Medicines Inc.
  • Aravives collaboration and license agreement with 3D Medicines Inc. is for the development and commercialization of batiraxcept in oncology indications in Greater China.
  • Under the terms of the agreement, Aravive is eligible to receive up to an aggregate of $207 million in development and commercial milestone payments and royalties.
  • In addition to achieving this $6 million development milestone, the Company had previously received a $9 million in development milestones related to development of batiraxcept for platinum resistant ovarian cancer in the United States and China, as well as a $12 million upfront payment in 2020, totaling $27 million that has been achieved by Aravive from 3D Medicines.

Clene Reports Second Quarter 2022 Financial Results and Recent Operating Highlights

Retrieved on: 
Monday, August 15, 2022
Employee Retirement Income Security Act of 1974, Hospital, Mortality, CEO, MS, CNM, Death, Population, Lists of diseases, GLOBE, R, Securities Exchange Act of 1934, Investment, COVID, Amyotrophic lateral sclerosis, Mitt, Massachusetts General Hospital, Annual report, LS, Neurodegeneration, Marketing, Quality of life, Patient, Review, COVID-19, Company, Letter, Twitter, European Network of Transmission System Operators for Electricity, Eye, Safety, ITT, Remyelination, Research, Neuroprotection, Securities Act of 1933, Gold, Nasdaq, SALT, LinkedIn, ALS, Cryptocurrency, Fine chemical, Pharmaceutical industry, Medical imaging, Hydraulic machinery, Medicine, Facebook

Presented five posters from the RESCUE-ALS trial at the European Network to Cure ALS (ENCALS) conference on June 1-3, 2022.

Key Points: 
  • Presented five posters from the RESCUE-ALS trial at the European Network to Cure ALS (ENCALS) conference on June 1-3, 2022.
  • Clene continues to support expanded access programs, providing CNM-Au8 treatment at five clinical sites for up to 55 total participants with ALS.
  • The ITT results were directionally consistent with the mITT results, although the ITT results were not significant.
  • Topline results for the ZnAg COVID Phase 2 clinical trial in acutely symptomatic, non-hospitalized COVID-19 patients in Brazil are expected this quarter.